Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Poster Discussion Abstracts

Combining Genomic Profiling (70 Gene-Mammaprint) with Nodal Status Allows To Classify Patients with Primary Breast Cancer and Positive Lymph Nodes (1-9) into Very Distinct Prognostic Subgroups That Could Help Tailor Treatment Strategies.

M. Saghatchian, S. Mook, G. Pruneri, G. Viale, A. Glas, I. Eekhout, S. Delaloge and L. van 't Veer
M. Saghatchian
1Institut Gustave Roussy, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Mook
2Netherlands Cancer Institute, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Pruneri
3European Institute of Oncology, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Viale
3European Institute of Oncology, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Glas
4Agendia BV, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I. Eekhout
2Netherlands Cancer Institute, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Delaloge
1Institut Gustave Roussy, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. van 't Veer
2Netherlands Cancer Institute, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/0008-5472.SABCS-09-102 Published December 2009
  • Article
  • Info & Metrics
Loading
Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX

Abstract

OBJECTIVESThe axillary lymph node (LN) status is considered to be one of the most important factors for chemotherapy decision-making of operable breast cancer patients (pts). It is commonly agreed that combination therapies with taxane-containing regimens should be recommended for these pts, whereas high-dose regimens have failed to provide further improvement for pts clinically considered at high-risk.It has previously been shown that the 70-gene profile (MammaPrint®TM), which was developed in node-negative patients is excellent in predicting disease outcome in pts with 1-3 positive nodes and similarly in pts with 4-9 positive-nodes. Further analysis based on adjuvant treatment received and pooled analysis of the 2 LN positive series was performed in order to assess the prognostic added-value of genomic profiling in LN positive pts.METHODS Frozen tumor samples from breast cancer pts with positive LN coming from 2 hospitals were selected in consecutive series (1-3 LN, 4-9 LN; all female, diagnosed between 1984 and 1995, primary invasive breast carcinoma, unilateral T1, T2 or operable T3, mastectomy or breast-conserving therapy, no prior malignancies, fresh frozen tumor material available). Samples were evaluated by gene expression profiling for the 70-gene profile and were classified as genomic high risk (poor prognosis) or genomic low risk (good prognosis).RESULTS A total of 519 pts have been analyzed: 346 with 1-3 positive LN (PN1) and 173 with 4-9 positive LN (PN2). Among them, 212 (41%) had the 70-gene good prognosis-profile and 307 (59%) had the 70-gene poor prognosis-profile (strictly equal proportions among the 2 LN groups). Median follow-up was 10.3 years: distant metastases occurred in 141 patients (116 as first event) and 103 (20 %) died of their disease. Distance metastases as first event and breast cancer specific survival according to LN group (PN) and genomic profile (MP) are shown in Figures 1 and 2.Embedded ImageEmbedded ImageCONCLUSION Our data show that the 70-gene profile is a strong prognostic marker of distant recurrence and breast specific death in breast cancer patients with positive LN. Combining nodal status (1-3 nodes vs. 4-9 nodes) and 70-gene profile (good vs. poor) allows stratifying patients among subgroups for whom tailored treatment strategies should be designed and assessed based on their very different outcome. Pts with elevated number of lymph nodes and high genomic risk have a very poor prognosis and might need to be considered for stronger treatment strategies.

Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 102.

Back to top
Cancer Research: 69 (24 Supplement)
December 2009
Volume 69, Issue 24 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Combining Genomic Profiling (70 Gene-Mammaprint) with Nodal Status Allows To Classify Patients with Primary Breast Cancer and Positive Lymph Nodes (1-9) into Very Distinct Prognostic Subgroups That Could Help Tailor Treatment Strategies.
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Combining Genomic Profiling (70 Gene-Mammaprint) with Nodal Status Allows To Classify Patients with Primary Breast Cancer and Positive Lymph Nodes (1-9) into Very Distinct Prognostic Subgroups That Could Help Tailor Treatment Strategies.
M. Saghatchian, S. Mook, G. Pruneri, G. Viale, A. Glas, I. Eekhout, S. Delaloge and L. van 't Veer
Cancer Res December 15 2009 (69) (24 Supplement) 102; DOI: 10.1158/0008-5472.SABCS-09-102

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Combining Genomic Profiling (70 Gene-Mammaprint) with Nodal Status Allows To Classify Patients with Primary Breast Cancer and Positive Lymph Nodes (1-9) into Very Distinct Prognostic Subgroups That Could Help Tailor Treatment Strategies.
M. Saghatchian, S. Mook, G. Pruneri, G. Viale, A. Glas, I. Eekhout, S. Delaloge and L. van 't Veer
Cancer Res December 15 2009 (69) (24 Supplement) 102; DOI: 10.1158/0008-5472.SABCS-09-102
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Poster Discussion Abstracts

  • Abstract PD7-09: Lasofoxifene decreases breast cancer lung and liver metastasis in a mammary intraductal (MIND) xenograft model of mutant ERα+ breast cancer
  • Abstract PD4-02: Withdrawn
  • Abstract PD2-04: Baseline circulating ESR1 mutation analysis in the randomised phase III EFECT study of fulvestrant versus exemestane in advanced hormone receptor positive breast cancer
Show more Poster Discussion Abstracts

Poster Discussion 1 - Multigene Prognostic Signatures

  • A BRCA1-Like, 25-Gene Assay Predicts for Anthracycline-Chemosensitivity in Sporadic Triple-Negative Breast Cancer.
  • Comparison of Prognostic Signatures in Node-Negative Tamoxifen-Treated Breast Cancer Patients.
  • A Genomic-Profile Derived Summary Measure of Chromosomal Breakpoints Predicts Response to Treatment with the DNA-Damaging Agent Cisplatin.
Show more Poster Discussion 1 - Multigene Prognostic Signatures

Multigene Prognostic Signatures - Prognostic Factors and Biomarkers-- Clinical Testing and Validation

  • Identification of a Prognostic Signature Based on the Expression of Insulin-Related Genes in Early Breast Cancer.
  • A Meta-Analysis of Gene Expression Profiling Studies Identifies Clinically Relevant Oncogenic Pathways in Basal-Like Breast Cancer.
  • Limited Clinical Utility of Prognostic Gene Expression Profiles in Grade 3 Node-Negative Early Stage Breast Cancer.
Show more Multigene Prognostic Signatures - Prognostic Factors and Biomarkers-- Clinical Testing and Validation
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement